591839
CD22, Epratuzumab Biosimilar
Size
£544.00
- SKU:
- 591839
- Purity:
- ≥95% (reducing SDS-PAGE, HPLC). Endotoxin: ≤1EU/mg (LAL)
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Human
- Immunogen:
- Recombinant protein corresponding to humam CD22, epratuzumab biosimilar, produced in mammalian cells.
- Format:
- Supplied as a 0.2uM filtered solution, pH 7.4. No stabilizers or preservatives added.
- Extra Details:
- Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IgG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). Applications: Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Epratuzumab. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
- Shipping Conditions:
- Blue Ice